Hematological Neoplasms

On May 1, 2018, the FDA approved Kymriah for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL). Kymriah is a CAR-T immunotherapy.

Kymriah, also known by its generic name tisagenlecleucel, is a groundbreaking cell therapy used to treat certain types of blood cancers.

Kymriah (tisagenlecleucel) is a groundbreaking CAR-T (Chimeric Antigen Receptor T-cell) therapy developed for the treatment of certain types of blood cancers.

Kymriah (tisagenlecleucel) represents a groundbreaking advancement in the field of immunotherapy. It is a chimeric antigen receptor (CAR) T-cell therapy designed to target CD19, a protein found on the surface of B cells.

Kymriah (tisagenlecleucel) represents a groundbreaking advancement in the field of cancer immunotherapy. As a chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah has set a new benchmark for treating various hematologic malignancies.

As of May 1, 2018, the FDA has approved Novartis’ CD19-targeted CAR-T therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Kymriah (tisagenlecleucel) is a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy developed by Novartis. It represents a novel approach to cancer treatment by using the patient’s own genetically modified T-cells to target and kill cancer cells.

Axicabtagene ciloleucel (axi-cel, Yescarta) and tisagenlecleucel (tisa-cel, Kymriah) were the first two CAR-T products approved in Europe for the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL) patients, and they have accumulated some real-world experience.